Details of the Drug Pharmacogenomic Perturbation Atlas

Entecavir Drug Info

Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate

Therapeutic Class

Antiviral Agents

Cross-matching ID

PubChem CID

135398508

ChEBI ID

CHEMBL473990

CAS Number

CAS 142217-69-4

TTD Drug ID

D0KR2J

VARIDT Drug ID

DR01277

ACDINA Drug ID

D00232

General Information of Drug (ID: DM7VTQO)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cell cycle	2.02	9.94e-3	110/124 (88.71%)	CDC20;CDC45;CDKN2C;...
One carbon pool by folate	1.87	2.98e-2	15/20 (75%)	TYMS;MTHFD1;AMT;...
Progesterone-mediated oocyte maturation	1.82	3.31e-2	75/100 (75%)	IGF1;CCNB1;CCNB2;...
Oocyte meiosis	1.81	3.23e-2	90/129 (69.77%)	CDC20;IGF1;CCNB1;...
DNA replication	1.76	4.57e-2	34/36 (94.44%)	MCM5;MCM7;MCM2;...
ECM-receptor interaction	1.74	4.31e-2	80/88 (90.91%)	COL6A1;COL6A2;CD36;...
Pentose and glucuronate interconversions	-1.86	2.01e-2	17/34 (50%)	CRYL1;UGP2;UGT2B28;...
Sphingolipid metabolism	-1.88	3.02e-2	32/49 (65.31%)	GAL3ST1;PLPP3;PLPP2;...
Oxidative phosphorylation	-2.06	0.00e+0	93/133 (69.92%)	COX11;COX5B;ATP5MC1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Normal (Fibroblast)

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H